Efficacy of immunotherapy in patients with non-small cell lung cancer
M. A. Lyadova,
E. A. Denisova,
D. S. Fedorinov,
Yu. S. Esakov,
A. S. Orlova,
D. A. Vozniuk,
K. V. Lyadov,
V. N. Galkin https://doi.org/10.21518/ms2023-451
Abstract
Introduction. Non-small cell lung cancer (NSCLC) is a form of lung cancer with high incidence and low overall survival. Immunotherapy is a promising treatment method for which the selection of optimal treatment regimens for each individual patient is important.
Aim. To evaluate the effectiveness and safety of immune checkpoint inhibitors (ICIs) in patients with advanced NSCLC.
Materials and methods. The study included 247 patients (190 men and 57 women) aged 37 to 87 years who received ICIs as monotherapy with nivolumab (n = 58; 23.4%), pembrolizumab (n = 78; 31.6%) and atezolizumab (n = 13; 5.3%), and in the form of combination chemoimmune therapy (n = 98; 39.7%). The objective response of the tumor to treatment was recorded in the presence of partial or complete regression of the tumor. The tumor response to treatment was determined in accordance with the iRECIST criteria.
Results. Objective response was achieved in 20.6% of patients, of which 13.7% were on the first line setting, and 7% of patients were on the 2nd or more line setting. Disease control was recorded in 83.3% of patients. Patients receiving combination chemoimmune therapy had a better response to treatment than those receiving monotherapy (χ2 = 9.309; p = 0.020). Grade 3–4 immuno-related adverse events were observed only in 5 (2.02%) patients.
Conclusions. NSCLC immunotherapy allows to achieve high rates of objective response and disease control (20.6 and 83.3%, respectively), with a small number of grade 3–4 immuno-related adverse events (2.02% according to our data), which indicates an acceptable safety profile.
Keywords
non-small cell lung cancer,
immunotherapy,
combined chemoimmune therapy,
immune-related adverse events
Supporting agencies: The authors express their gratitude to the team of the Oncology Department No. 1 of the Moscow Center for Rehabilitation Treatment: E.S. Chernyshova, A.A. Kosmynin, R.R. Shakirov, D.S. Shakirova, T.R. Eynullaeva, A.I. Tekeeva, Ya.V. Koroleva, A.A. Ploschik, as well as the administrator of the chemotherapy department No. 1 of the City Clinical Oncology Hospital No. 1 R. Blazhentseva.
About the Authors
M. A. Lyadova
Moscow City Oncological Hospital No. 1; Novokuznetsk State Institute for Postgraduate Medical Education – a branch of the Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Marina A. Lyadova - Cand. Sci. (Med.), Head of Chemotherapy Department No. 1, Moscow City Oncological Hospital No. 1; Department Assistant, Novokuznetsk State Institute for Postgraduate Medical Education – a branch of the Russian Medical Academy of Continuous Professional Education.
18A, Bldg. 7, Zagorodnoe Shosse, Moscow, 117152; 5, Stroiteley Ave., Novokuznetsk, 654005
E. A. Denisova
Moscow City Oncological Hospital No. 1
Russian Federation
Russian Federation
Elena A. Denisova - Cand. Sci. (Med.), Oncologist, Chemotherapy Department No. 1, Moscow City Oncological Hospital No. 1.
18A, Bldg. 7, Zagorodnoe Shosse, Moscow, 117152
D. S. Fedorinov
Moscow City Oncological Hospital No. 1; Russian Medical Academy of Continuous Professional Education
Russian Federation
Russian Federation
Denis S. Fedorinov - Oncologist, Chemotherapy Department No. 1, Moscow City Oncological Hospital No. 1; Senior Assistant, Russian Medical Academy of Continuous Professional Education.
18A, Bldg. 7, Zagorodnoe Shosse, Moscow, 117152; 2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993
Yu. S. Esakov
Moscow City Oncological Hospital No. 1
Russian Federation
Russian Federation
Yuri S. Esakov - Cand. Sci. (Med.), Head of the Thoracic Department, Moscow City Oncological Hospital No. 1.
18A, Bldg. 7, Zagorodnoe Shosse, Moscow, 117152
A. S. Orlova
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Aleksandra S. Orlova - Cand. Sci. (Med.), Associate Professor, Associate Professor of the Department of Human Pathology, Institute of Biodesign and Modeling of Complex Systems, Scientific and Technological Park of Biomedicine, Sechenov First Moscow State Medical University (Sechenov University).
8, Bldg. 2, Trubetskaya St., Moscow, 119991
D. A. Vozniuk
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Dmitrii A. Vozniuk - Assistant of the Department of Molecular Biology, Pirogov Russian National Research Medical University.
1, Ostrovityanov St., Moscow, 117997
K. V. Lyadov
Moscow Center for Rehabilitation
Russian Federation
Russian Federation
Konstantin V. Lyadov - Acad. RAS, Dr. Sci. (Med.), Professor, Honored Doctor of the Russian Federation, General Director, Moscow Center for Rehabilitation.
16, Bldg. 1, Orshanskaya St., Moscow, 121552
V. N. Galkin
Moscow City Oncological Hospital No. 1
Russian Federation
Russian Federation
Vsevolod N. Galkin - Dr. Sci. (Med.), Professor, Chief Physician, Moscow City Oncological Hospital No. 1.
18A, Bldg. 7, Zagorodnoe Shosse, Moscow, 117152
References
1. Huang J, Deng Y, Tin MS, Lok V, Ngai CH, Zhang L et al. Distribution, Risk Factors, and Temporal Trends for Lung Cancer Incidence and Mortality: A Global Analysis. Chest. 2022;161(4):1101–1111. https://doi.org/10.1016/j.chest.2021.12.655.
2. Martin-Gisbert L, Ruano-Ravina A, Varela-Lema L, Penabad M, Giraldo- Osorio A, Candal-Pedreira C et al. Lung cancer mortality attributable to residential radon: a systematic scoping review. J Expo Sci Environ Epidemiol. 2023;33(3):368–376. https://doi.org/10.1038/s41370-022-00506-w.
3. Yudin DI, Laktionov KK, Moiseenko FV, Ponomarenko DM, Chekh EA, Chubenko VA et al. First results of durvalumab after chemoradiotherapy in locally advanced non-small-cell lung cancer in Russia. Meditsinskiy Sovet. 2022;(22):12–20. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-22-12-20.
4. Cabezón-Gutiérrez L, Sereno M, Cervera-Calero R, Mielgo-Rubio X, Higuera O. High tumor burden in non-small-cell lung cancer: A review of the literature. J Clin Transl Res. 2022;8(5):403–413. https://doi.org/10.18053/jctres.08.202205.008.
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–98. https://doi.org/10.1056/NEJMoa011954.
6. Puri S, Shafique M. Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies. Drugs Context. 2020;9:2019-9-2. https://doi.org/10.7573/dic.2019-9-2.
7. Qu J, Mei Q, Liu L, Cheng T, Wang P, Chen L, Zhou J. The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer. Ther Adv Med Oncol. 2021;13:1758835921992968. https://doi.org/10.1177/1758835921992968.
8. Rossi A, Di Maio M. Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles. Expert Rev Anticancer Ther. 2016;16(6):653–660. https://doi.org/10.1586/14737140.2016.1170596.
9. Bodor JN, Kasireddy V, Borghaei H. First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation. J Oncol Pract. 2018;14(9):529–535. https://doi.org/10.1200/JOP.18.00250.
10. Xuan Y, Guan M, Zhang S. Tumor immunotherapy and multi-mode therapies mediated by medical imaging of nanoprobes. Theranostics. 2021;11(15):7360–7378. https://doi.org/10.7150/thno.58413.
11. Ellis PM, Vella ET, Ung YC. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review. Clin Lung Cancer. 2017;18(5):444–459.e1. https://doi.org/10.1016/j.cllc.2017.02.001.
12. Nagano T, Tachihara M, Nishimura Y. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. Curr Cancer Drug Targets. 2019;19(8):595–630. https://doi.org/10.2174/1568009619666181210114559.
13. Broderick SR. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer. Thorac Surg Clin. 2020;30(2):215–220. https://doi.org/10.1016/j.thorsurg.2020.01.001.
14. Доможирова АС, Трофименко ИА, Гележе ПБ, Липкина ЕА, Мокиенко ОА, Морозов СП. iRECIST: критерии оценки ответов опухолей на иммуно терапию: методические рекомендации №37. М.; 2021. 28 с. Режим доступа: https://mosgorzdrav.ru/ru-RU/science/default/download/887.html.
15. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(22):2078–2092. https://doi.org/10.1056/NEJMoa1801005.
16. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a ran-domised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497–1508. https://doi.org/10.1016/S1470-2045(16)30498-3.
17. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823–1833. https://doi.org/10.1056/NEJMoa1606774.
18. Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Soto Parra H, Mazières J et al. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407. J Thorac Oncol. 2020;15(10):1657–1669. https://doi.org/10.1016/j.jtho.2020.06.015.
19. Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J et al. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol. 2021;39(7):723–733. https://doi.org/10.1200/JCO.20.01605.
20. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017;376(25):2415–2426. https://doi.org/10.1056/NEJMoa1613493.
21. Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381(21):2020–2031. https://doi.org/10.1056/NEJMoa1910231.
22. Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198–211. https://doi.org/10.1016/S1470-2045(20)30641-0.
23. Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N et al. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34(25):2980–2987. https://doi.org/10.1200/JCO.2016.66.9929.
24. Vaddepally R, Doddamani R, Sodavarapu S, Madam NR, Katkar R, Kutadi AP et al. Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)-Their Incidence, Management, Multiorgan irAEs, and Rechallenge. Biomedicines. 2022;10(4):790. https://doi.org/10.3390/biomedicines10040790.
25. Zhang W, Gu J, Bian C, Huang G. Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials. Front Pharmacol. 2021;12:686876. https://doi.org/10.3389/fphar.2021.686876.
26. Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW et al. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Front Pharmacol. 2017;8:730. https://doi.org/10.3389/fphar.2017.00730.
27. Akamatsu H, Murakami E, Oyanagi J, Shibaki R, Kaki T, Takase E et al. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer. Oncologist. 2020;25(4):e679–e683. https://doi.org/10.1634/theoncologist.2019-0299.
28. Pillai RN, Behera M, Owonikoko TK, Kamphorst AO, Pakkala S, Belani CP et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. Cancer. 2018;124(2):271–277. https://doi.org/10.1002/cncr.31043.
29. Huang MY, Jiang XM, Wang BL, Sun Y, Lu JJ. Combination therapy with PD-1/ PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. Pharmacol Ther. 2021;219:107694. https://doi.org/10.1016/j.pharmthera.2020.107694.
30. Guo X, Chen S, Wang X, Liu X. Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies. Front Immunol. 2023;14:1138483. https://doi.org/10.3389/fimmu.2023.1138483.
Review
For citations:
Lyadova MA, Denisova EA, Fedorinov DS, Esakov YS, Orlova AS, Vozniuk DA, Lyadov KV, Galkin VN. Efficacy of immunotherapy in patients with non-small cell lung cancer. Meditsinskiy sovet = Medical Council. 2023;(22):30-39. (In Russ.) https://doi.org/10.21518/ms2023-451
Views:
335
Email this article 